Purchase of shares and PDMR notification
Updated : 07:06
24 March 2020
Purchase of shares and PDMR notification
Clinigen Group plc (AIM: CLIN, "Clinigen" or the "Company"), announces that, on 23 March 2020, two directors and one of the senior management team purchased ordinary shares of £0.01p each in the Group. Shaun Chilton bought 10,000 shares, Nick Keher 6,200 shares and David Bryant 4,763 shares.
Shaun Chilton, Group Chief Executive Officer, said:
"Our share purchases are a strong endorsement of our strategy and underlie our belief in the Company and its prospects.
"We are the world experts in providing access to medicines across borders and we are working hard to support Hospital Pharmacists and Physicians across the US, EU and AAA region to help their patients in the current Coronavirus situation.
"We are confident of the continuing demand for our Clinical and Unlicensed Medicines services, and for our portfolio of hospital oncology and anti-infective medicines."
The notifications below, made in accordance with the requirements of the EU Market Abuse Regulation, provide further detail.
-Ends-
Contact Details
Clinigen Group plc | Tel: +44 (0) 1283 495 010 |
Shaun Chilton, Group Chief Executive Officer Nick Keher, Group Chief Financial Officer Matt Parrish, Head of Investor Relations |
|
|
|
Numis Securities Limited - Nominated Adviser & Joint Broker | Tel: +44 (0) 20 7260 1000 |
James Black / Freddie Barnfield |
|
RBC Capital Markets - Joint Broker | Tel: +44 (0) 20 7653 4000 |
Marcus Jackson / Elliot Thomas |
|
| |
Instinctif Partners | Tel: +44 (0) 20 7457 2020 |
Adrian Duffield / Melanie Toyne-Sewell / Phillip Marriage | Email: clinigen@instinctif.com |
Notes to Editors
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. The Group has sites in North America, Europe, Africa and Asia Pacific.
Clinigen now has over 1,100 employees across five continents in 14 countries, with supply and distribution hubs and operational centres of excellence in key long-term growth regions. The Group works with 22 of the top 25 pharmaceutical companies; interacting with over 15,000 registered users across over 100 countries, shipping approximately 6.4 million units in the year.
For more information on Clinigen, please visit www.clinigengroup.com
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1 | Details of the person discharging managerial responsibilities/person closely associated | ||
a) | Name | Shaun Chilton | |
2 | Reason for the notification | ||
a) | Position/status | Chief Executive Officer | |
b) | Initial notification /Amendment | Initial Notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Clinigen Group plc | |
b) | Legal Entity Identifier | 213800OBIKGI2JYYS227 | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument
Identification code | Ordinary shares of 0.1 pence each
GB00B89J2419 | |
b) | Nature of the transaction | Purchase of shares | |
c) | Currency | GBP | |
d) | Price(s) and volume(s) | Price(s) | Volume(s) |
415.5p per share | 10,000 shares | ||
| |||
e) | Aggregated information - Aggregated volume - Price - Aggregated total |
10,000 shares 415.5p £41,550 | |
f) | Date of the transaction | 23 March 2020 | |
g) | Place of the transaction | London Stock Exchange, AIM | |
1 | Details of the person discharging managerial responsibilities/person closely associated | ||
a) | Name | Nick Keher | |
2 | Reason for the notification | ||
a) | Position/status | Chief Financial Officer | |
b) | Initial notification /Amendment | Initial Notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Clinigen Group plc | |
b) | Legal Entity Identifier | 213800OBIKGI2JYYS227 | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument
Identification code | Ordinary shares of 0.1 pence each
GB00B89J2419 | |
b) | Nature of the transaction | Purchase of shares | |
c) | Currency | GBP | |
d) | Price(s) and volume(s) | Price(s) | Volume(s) |
400p per share | 6,200 shares | ||
| |||
e) | Aggregated information - Aggregated volume - Price - Aggregated total |
6,200 shares 400p £24,800 | |
f) | Date of the transaction | 23 March 2020 | |
g) | Place of the transaction | London Stock Exchange, AIM | |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.